We currently looked at the effect of CCR6 deletion to examine the role of the CCL20/CCR6 axis, but the targeting of CCL20 should be investigated as well in order to clarify which target is more appropriate to restore the disease process associated with CCL20/CCR6 axis in the context of SSc pathology. This evidence concerns the gene CCL20 and systemic sclerosis.